Biblio

Export 10 results:
Author Keyword Title [ Type(Asc)] Year
Filters: Author is Fagan, Anne M  [Clear All Filters]
Journal Article
R. A. Sperling, Aisen, P. S., Beckett, L. A., Bennett, D. A., Craft, S., Fagan, A. M., Iwatsubo, T., Jack, C. R., Kaye, J., Montine, T. J., Park, D. C., Reiman, E. M., Rowe, C. C., Siemers, E., Stern, Y., Yaffe, K., Carrillo, M. C., Thies, B., Morrison-Bogorad, M., Wagster, M. V., and Phelps, C. H., Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease., Alzheimers Dement, vol. 7, no. 3, pp. 280-92, 2011.
S. L. Allison, Fagan, A. M., Morris, J. C., and Head, D., Spatial Navigation in Preclinical Alzheimer's Disease., J Alzheimers Dis, vol. 52, no. 1, pp. 77-90, 2016.
P. Chatterjee, Lim, W. L. F., Shui, G., Gupta, V. B., James, I., Fagan, A. M., Xiong, C., Sohrabi, H. R., Taddei, K., Brown, B. M., Benzinger, T., Masters, C., Snowden, S. G., Wenk, M. R., Bateman, R. J., Morris, J. C., and Martins, R. N., Plasma Phospholipid and Sphingolipid Alterations in Presenilin1 Mutation Carriers: A Pilot Study., J Alzheimers Dis, vol. 50, no. 3, pp. 887-94, 2016.
G. M. Babulal, Stout, S. H., Head, D., Holtzman, D. M., Fagan, A. M., Morris, J. C., and Roe, C. M., Neuropsychiatric Symptoms and Alzheimer's Disease Biomarkers Predict Driving Decline: Brief Report., J Alzheimers Dis, vol. 58, no. 3, pp. 675-680, 2017.
J. M. Castellano, Kim, J., Stewart, F. R., Jiang, H., DeMattos, R. B., Patterson, B. W., Fagan, A. M., Morris, J. C., Mawuenyega, K. G., Cruchaga, C., Goate, A. M., Bales, K. R., Paul, S. M., Bateman, R. J., and Holtzman, D. M., Human apoE isoforms differentially regulate brain amyloid-β peptide clearance., Sci Transl Med, vol. 3, no. 89, p. 89ra57, 2011.
D. Head, Bugg, J. M., Goate, A. M., Fagan, A. M., Mintun, M. A., Benzinger, T., Holtzman, D. M., and Morris, J. C., Exercise Engagement as a Moderator of the Effects of APOE Genotype on Amyloid Deposition., Arch Neurol, vol. 69, no. 5, pp. 636-43, 2012.
G. M. Babulal, Chen, S., Williams, M. M., Trani, J. - F., Bakhshi, P., Chao, G. L., Stout, S. H., Fagan, A. M., Benzinger, T. L. S., Holtzman, D. M., Morris, J. C., and Roe, C. M., Depression and Alzheimer's Disease Biomarkers Predict Driving Decline., J Alzheimers Dis, vol. 66, no. 3, pp. 1213-1221, 2018.
A. P. Ingber, Hassenstab, J., Fagan, A. M., Benzinger, T. L. S., Grant, E. A., Holtzman, D. M., Morris, J. C., and Roe, C. M., Cerebrospinal Fluid Biomarkers and Reserve Variables as Predictors of Future "Non-Cognitive" Outcomes of Alzheimer's Disease., J Alzheimers Dis, vol. 52, no. 3, pp. 1055-64, 2016.
P. Lewczuk, Matzen, A., Blennow, K., Parnetti, L., Molinuevo, J. Luis, Eusebi, P., Kornhuber, J., Morris, J. C., and Fagan, A. M., Cerebrospinal Fluid Aβ42/40 Corresponds Better than Aβ42 to Amyloid PET in Alzheimer's Disease., J Alzheimers Dis, vol. 55, no. 2, pp. 813-822, 2017.
J. C. Morris, Roe, C. M., Xiong, C., Fagan, A. M., Goate, A. M., Holtzman, D. M., and Mintun, M. A., APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging., Ann Neurol, vol. 67, no. 1, pp. 122-31, 2010.